Processa Pharmaceuticals, Inc. Retained Earnings
Processa Pharmaceuticals, Inc. (PCSA) had Retained Earnings of -$107.43 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$107.43M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$104.16M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$100.78M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$97.42M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$107.43M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$104.16M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$100.78M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$97.42M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$93.99M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$90.05M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$87.22M 10-K · filed 2026-03-18 | |
| 2024-09-30 | -$84.49M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | -$81.11M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$78.10M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | -$75.37M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$72.96M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$70.88M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$68.27M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$64.25M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$51.24M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$45.21M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$40.05M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$36.82M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$33.64M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$30.65M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$27.50M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$25.40M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$15.66M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$12.59M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$11.86M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$10.98M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$10.21M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$9.34M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$8.37M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$7.62M 10-K · filed 2020-03-06 | |
| 2018-09-30 | -$7.01M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$6.16M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$4.96M 10-Q · filed 2018-05-21 | |
| 2017-12-31 | -$3.86M 10-K/A · filed 2019-04-08 | |
| 2017-09-30 | -$17.04M 10-Q · filed 2017-11-20 | |
| 2017-06-30 | -$15.39M 10-Q · filed 2017-10-04 | |
| 2017-03-31 | -$15.34M 10-Q · filed 2017-10-04 | |
| 2016-12-31 | -$2.00M 10-K · filed 2018-04-16 | -$15.25M 10-K · filed 2017-09-25 |
| 2016-09-30 | -$15.15M 10-Q · filed 2017-09-08 | |
| 2016-06-30 | -$15.07M 10-Q · filed 2017-08-30 | |
| 2016-03-31 | -$15.02M 10-Q · filed 2017-08-07 | |
| 2015-12-31 | -$14.87M 10-K · filed 2017-09-25 | |
| 2015-09-30 | -$15.93M 10-Q · filed 2015-12-01 | |
| 2015-06-30 | -$15.62M 10-Q · filed 2015-08-19 | |
| 2015-03-31 | -$13.56M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | -$11.85M 10-K · filed 2017-06-19 | -$12.91M 10-K · filed 2015-04-14 |
| 2014-09-30 | -$10.00M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$9.13M 10-Q · filed 2014-08-19 | |
| 2013-12-31 | -$6.81M 10-K · filed 2015-04-14 | |
| 2013-09-30 | -$5.96M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | -$5.03M 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |